Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SLC6A15 | Q9H2J7 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490594 | 0.87 | HRH1 (0.42) | HRH1KCNH2SLC6A15MAPTMEN1 | |
| SCHEMBL490493 | 0.85 | ROCK2 (0.48) | ROCK2KCNH2ALDH1A1PIK3CAPIK3CB | |
| SCHEMBL490273 | 0.79 | OPRD1 (0.46) | ROCK2KCNH2OPRM1PIK3CAPIK3CB | |
| SCHEMBL490378 | 0.79 | ROCK2 (0.48) | ROCK2KCNH2CYP2D6OPRK1PIK3CA | |
| SCHEMBL9168240 | 0.78 | PTAFR (0.58) | HRH1KCNH2SLC6A15MAPTMEN1 | |
| SCHEMBL12065129 | 0.78 | HRH1 (0.61) | HRH1KCNH2SLC6A15MAPTMEN1 | |
| SCHEMBL3138906 | 0.76 | ROCK2 (0.45) | ROCK2KCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9718766 | 0.76 | HRH1 (0.61) | HRH1KCNH2SLC6A15MAPTMEN1 | |
| SCHEMBL5905792 | 0.76 | SETD7 (0.49) | HRH1KCNH2SLC6A15MAPTMEN1 | |
| SCHEMBL12065130 | 0.76 | KCNH2 (0.57) | HRH1KCNH2SLC6A15MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2011-10-06 | — | — | US | disclosed |
| US-7982042-B2 | delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions;N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-yl]-phenyl}-acetamide | Janseen Pharmacautica NV (BE) | 2011-07-19 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HRH1 584/4885ROCK2 2549/4885KCNH2 618/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HRH1 584/4885ROCK2 2549/4885KCNH2 618/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | HRH1 584/4885ROCK2 2549/4885KCNH2 618/4885 |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HRH1 584/4885ROCK2 2549/4885KCNH2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.